Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective ...

Novo Nordisk, the maker of Wegovy, will focus on commercial strategy and cost reduction. This decision follows a profit ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit today, but rising competition is ...

Sales of Novo Nordisk’s diabetes drugs including Ozempic slowed to grow at 8 per cent year on year in the first half, down sharply from its rate last year, as the company loses market share to rival ...

Partially as a result, Novo Nordisk stock has steadily declined since last summer. Over the past year, NVO shares are down ...

Novo, valued at $650 billion in June last year, has shed over two-thirds of its value since. Its latest market cap is around ...

Novo Nordisk has appointed Maziar Mike Doustdar as CEO, replacing Lars Fruergaard, to address recent market challenges.

Effective August 7, 2025, Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as Novo Nordisk president and chief ...